Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).
Invest New Drugs
; 33(4): 985-91, 2015 Aug.
Article
in En
| MEDLINE
| ID: mdl-26084990
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Nasopharyngeal Neoplasms
/
Protein Kinase Inhibitors
/
Heterocyclic Compounds, 3-Ring
/
Neoplasm Recurrence, Local
/
Antineoplastic Agents
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Invest New Drugs
Year:
2015
Type:
Article